Who are Trovert's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ngenla, Ngenla, Skytrofa, Sogroya, Trovert, GH treatment (Genotropin).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegvisomant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Trovert — Competitive Intelligence Brief

Trovert (PEGVISOMANT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth Hormone Receptor Antagonist. Area: Other.

marketed Growth Hormone Receptor Antagonist Growth hormone receptor Other Recombinant protein Live · refreshed every 30 min

Target snapshot

Trovert (PEGVISOMANT) — Pfizer. Pegvisomant works by binding to the growth hormone receptor, blocking the action of growth hormone and preventing excessive growth and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trovert TARGET	PEGVISOMANT	Pfizer	marketed	Growth Hormone Receptor Antagonist	Growth hormone receptor	2003-01-01
Ngenla	somatrogon	Pfizer Ireland Pharmaceuticals	marketed		Growth hormone receptor	2023-01-01
Ngenla	Somatrogon-Ghla	Pfizer Ireland Pharmaceuticals	marketed		Growth hormone receptor	2023-01-01
Skytrofa	LONAPEGSOMATROPIN	Ascendis Pharma Encocrinology Div A/S	marketed	Recombinant Human Growth Hormone [EPC]	Growth hormone receptor	2021-01-01
Sogroya	SOMAPACITAN	Novo Nordisk	marketed		Growth hormone receptor	2020-01-01
Trovert	somavert	Pfizer	marketed	Growth Hormone Receptor Antagonist	Growth hormone receptor	2003-01-01
GH treatment (Genotropin)	GH treatment (Genotropin)	Rabin Medical Center	marketed	Recombinant human growth hormone (somatropin)	Growth hormone receptor (GHR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth Hormone Receptor Antagonist class)

Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trovert — Competitive Intelligence Brief. https://druglandscape.com/ci/pegvisomant. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab